The AMA announced a new policy that supports requirements for drug and device sponsors to develop diversity action plans so that women and sexual and gender minorities are adequately represented in their clinical trials.
The policy also backs efforts from the FDA to condition the approval of drugs and devices on postmarketing research that includes safety and efficacy data on women and sexual and gender minorities (SGM) when these groups were not amply represented in the clinical trials, according to a press release.
Additionally, the policy encourages the NIH and other grantmakers to fund